Harvard Drug Group Recalls Fluconazole Tablets for Failed Dissolution
The Harvard Drug Group is recalling 2,341 cartons of Fluconazole 100 mg tablets because they failed to meet dissolution specifications.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as FDA Class II, which typically involves a temporary or medically reversible adverse health consequence. The specific defect is a failure to meet dissolution specifications, which is a quality control issue rather than a direct contamination or mislabeling of a common allergen.
Plain-English summary
The Harvard Drug Group is voluntarily recalling 2,341 cartons of Fluconazole Tablets, USP, 100 mg. The product is distributed nationwide in the United States. The recall was initiated because the tablets failed to meet required dissolution specifications.
The affected product is a prescription-only medication manufactured by Dr. Reddy's Laboratories Limited in India and distributed by Major Pharmaceuticals. The specific lots involved are T-00520, T-00632, and T-00699, with expiration dates of 02-17 and 04-17. The National Drug Codes (NDC) for the affected packaging are 0904-6500-61 and 0904-6501-61.
Consumers and healthcare providers should check their inventory for these specific lot numbers and expiration dates. If the product is found, it should be returned to the distributor or disposed of according to local regulations. Patients should consult their healthcare provider for alternative treatment options if they have been prescribed this specific medication.
The recalled product
- Product
- FLUCONAZOLE (FLUCONAZOLE)
- Brand
- FLUCONAZOLE
- Manufacturer
- The Harvard Drug Group
- Category
- Drug — Antifungal
- Hazard
- Affected units
- 2,341
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (5)
- Lot#: T-00520
- EXP 02-17
- T-00632
- T-00699
- EXP. 04-17
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 2 recalled by The Harvard Drug Group under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 2 products in this recall →Related recalls
Same brand · FLUCONAZOLE
- SevereBaxter Recalls Fluconazole Injection Bags Due to Sterility Concerns
FDA (Drugs) · 2017-05-24
- ModerateFluconazole Tablets Recalled for Failed Dissolution Specifications
FDA (Drugs) · 2017-05-10
- ModerateDr. Reddy's Recalls Flucanazole Tablets for Dissolution Failures
FDA (Drugs) · 2017-02-08
- HighDr. Reddy's Recalls Flucanazole Tablets for Dissolution Failures
FDA (Drugs) · 2017-02-08
- ModerateDr. Reddy's Recalls Flucanazole Tablets Due to Dissolution Failures
FDA (Drugs) · 2017-02-08
Same manufacturer · The Harvard Drug Group
See all →- ModerateTramadol Hydrochloride Tablets Recalled Due to Inadequate Blister Packaging Seal
FDA (Drugs) · 2023-07-05
- ModerateGabapentin tablets recalled due to product mixup with foreign tablet
FDA (Drugs) · 2023-05-17
- HighCarbidopa and Levodopa Tablets Recalled for Inadequate Blister Packaging Seal
FDA (Drugs) · 2023-03-08
- ModeratehydrALAZINE HCl Tablets 10 mg Recalled for Failed Impurity Specifications
FDA (Drugs) · 2022-03-23
- ModeratePaliperidone Extended-Release Tablets Recalled for Failed Dissolution
FDA (Drugs) · 2022-03-16
Same hazard · failed dissolution
See all →- ModerateNovartis Recalls Diovan Valsartan Tablets Due to Failed Dissolution Specifications
FDA (Drugs) · 2026-08-19
- LowSupernus Recalls Trokendi XR Capsules for Failed Dissolution Specifications
FDA (Drugs) · 2026-07-29
- HighAscend amlodipine and olmesartan tablets failed dissolution specifications
FDA (Drugs) · 2026-06-10
- HighLannett niacin extended-release tablets failed dissolution specifications during stability
FDA (Drugs) · 2026-06-10
- HighMajor Pharmaceuticals memantine extended-release capsules fail dissolution specifications
FDA (Drugs) · 2026-04-22